Reporte zur Charge 048L21A CU51108

Symptomtext

COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient. A 58-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07Apr2022 as dose 4 (booster), single (Lot number: 048L21A CU511081) at the age of 57 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ROSUVASTATIN. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Aug2022, outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: Treatment for covid-19 Test; (Aug2022) Negative, notes: On day 8 after testing positive; (Aug2022) Positive, notes: On day 7 after testing positive; (Aug2022) Positive, notes: A rapid antigen test was only faintly negative; (Aug2022) Positive, notes: a rapid antigen test was strongly positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid. Clinical Course: It was reported that on day 7 after testing positive, her COVID symptoms were very minor and a rapid antigen test was only faintly negative. On day 8 after testing positive, her COVID symptoms resumed and a rapid antigen test was strongly positive. It is now day 9 and her symptoms and test results are still strong. The patient received treatment with Paxlovid from 14Aug2022 to 18Aug2022. The patient received other medication within 2 weeks of vaccination. The patient had no known allergies and no other medical history.